Virax Biolabs GroupVRAX +1.29%29 PB Ratio is 0.33 as of Jul. 07, 2026, which is 41% below its 10-year median of 0.56. GuruFocus rates VRAX with a GF Score™ of 29/100 and a GF Value™ of $1.15 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,226 Biotechnology companies, Virax Biolabs Group ranks better than 98.94% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Virax Biolabs Group PB Ratio Related Terms
Virax Biolabs Group PB Ratio Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Virax Biolabs Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virax Biolabs Group PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Virax Biolabs Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Virax Biolabs Group (VRAX) has a PB Ratio of 0.33 as of Jul. 07, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Virax Biolabs Group and its competitors. This is 41% below median its historical median of 0.56. Over the past decade, Virax Biolabs Group's PB Ratio has ranged from 0.08 to 2.61. According to the industry distribution chart, Virax Biolabs Group ranks #13 out of 1226 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Virax Biolabs Group's PB Ratio too high?
Virax Biolabs Group's current PB Ratio of 0.33 is 41% below median its 10-year median of 0.56. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 2.61. The Biotechnology industry median PB Ratio is 2.91. Virax Biolabs Group's value of 0.33 is 88.7% below this industry median. Based on the distribution chart, Virax Biolabs Group ranks #13 out of 1226 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Virax Biolabs Group has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's PB Ratio compare to BBLG and PKTX?
According to the Biotechnology industry distribution chart, Virax Biolabs Group ranks #13 out of 1226 companies for PB Ratio. This places Virax Biolabs Group in the top 1% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.91. Virax Biolabs Group's value of 0.33 is 88.7% below this benchmark. Historically, Virax Biolabs Group's own PB Ratio has ranged from 0.08 to 2.61 over the past decade. While the company's 10-year median is 0.56 vs. the industry median of 2.91, Virax Biolabs Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.91, based on 1,226 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virax Biolabs Group's current PB Ratio of 0.33 is 88.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Virax Biolabs Group and its competitors. For the Biotechnology industry, the median PB Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virax Biolabs Group's current PB Ratio is 0.33, which is 41% below median its own 10-year median of 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.15, compared to a current price of $3.13 — trading 172.2% above its estimated fair value. The current PB Ratio is 0.33, which is 41% below median its 10-year median of 0.56 and 88.7% below the Biotechnology industry median of 2.91. Virax Biolabs Group's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current PB Ratio is 0.33 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued.
The current stock price of $3.13 is trading 172.2% above its estimated GF Value™ of $1.15.
GuruFocus considers Virax Biolabs Group to be Significantly Overvalued.
Key valuation signals for VRAX:
PB Ratio: 0.33 (41% below median its 10-year median of 0.56)
GF Value™: $1.15 vs. price of $3.13 (172.2% above fair value)
Industry Position: 88.7% below the Biotechnology median (#13 of 1226)
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
29GF Score
Get the complete analysis for VRAX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
